Report NEP-IPR-2007-04-09

This is the archive for NEP-IPR, a report on new working papers in the area of Intellectual Property Rights. Roland Kirstein issued this report. It is usually issued weekly.

Subscribe to this report: email, RSS, or Mastodon.

Other reports in NEP-IPR

The following items were announced in this report:

• Czarnitzki, Dirk & Toole, Andrew A., 2006. "Patent protection, market uncertainty, and R&D investment," ZEW Discussion Papers 06-056, ZEW - Leibniz Centre for European Economic Research.
• Frey, Rainer & Hussinger, Katrin, 2006. "The Role of Technology in M&As: A Firm Level Comparison of Cross-Border and Domestic Deals," ZEW Discussion Papers 06-069, ZEW - Leibniz Centre for European Economic Research.
• Dean Baker, 2007. "Stagnation in the Drug Development Process: Are Patents the Problem?," CEPR Reports and Issue Briefs 2007-07, Center for Economic and Policy Research (CEPR).
• Czarnitzki, Dirk & Toole, Andrew A., 2006. "Business R&D and the Interplay of R&D Subsidies and Market Uncertainty," ZEW Discussion Papers 06-055, ZEW - Leibniz Centre for European Economic Research.
• Aerts, Kris & Schmidt, Tobias, 2006. "Two for the price of one? On additionality effects of R&D subsidies: A comparison between Flanders and Germany," ZEW Discussion Papers 06-063, ZEW - Leibniz Centre for European Economic Research.
• Sinha, Dipendra, 2007. "Patents, Innovations and Economic Growth in Japan and South Korea: Evidence from individual country and panel data," MPRA Paper 2547, University Library of Munich, Germany.
• Pattikawa, L.H., 2007. "Longitudinal Study on the Performance of U.S. Pharmaceutical Firms: The Increasing Role of Marketing," ERIM Report Series Research in Management ERS-2007-020-STR, Erasmus Research Institute of Management (ERIM), ERIM is the joint research institute of the Rotterdam School of Management, Erasmus University and the Erasmus School of Economics (ESE) at Erasmus University Rotterdam.
• Iván Moreno Torres & Jaume Puig & Joan-Ramon Borrell-Arqué, 2007. "Generic entry into a regulated pharmaceutical market," Working Papers, Research Center on Health and Economics 1014, Department of Economics and Business, Universitat Pompeu Fabra.